+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

State and demographic variation in use of depot antipsychotics by Medicaid beneficiaries with schizophrenia



State and demographic variation in use of depot antipsychotics by Medicaid beneficiaries with schizophrenia



Psychiatric Services 65(1): 121-124



This study examined state and demographic variation in use of depot antipsychotics among Medicaid beneficiaries with schizophrenia. Medicaid claims data (2007) from 21 states and the District of Columbia were analyzed for 102,884 beneficiaries age 18 to 64 with schizophrenia. Rates of receipt of depot antipsychotics were determined for all beneficiaries and for African Americans, Caucasians, and beneficiaries from "all other races." Across study states, a mean of 10% of beneficiaries with schizophrenia received depot antipsychotics. Rates ranged from 1.9% in the District of Columbia to 20.9% in Alabama. In 12 states, African Americans were disproportionately likely to receive these medications compared with beneficiaries of other races. Use of depot antipsychotics varied across state Medicaid programs. African Americans received a disproportionate share in many states. Further research is needed to understand the sources of such variation. These findings underscore the need to monitor the use of depot antipsychotics.

(PDF emailed within 0-6 h: $19.90)

Accession: 055908521

Download citation: RISBibTeXText

PMID: 24382765

DOI: 10.1176/appi.ps.201300001


Related references

State Variation in the Delivery of Comprehensive Services for Medicaid Beneficiaries with Schizophrenia and Bipolar Disorder. Community Mental Health Journal 51(5): 523-534, 2016

Antipsychotics and the Risks of Sudden Cardiac Death and All-Cause Death: Cohort Studies in Medicaid and Dually-Eligible Medicaid-Medicare Beneficiaries of Five States. Journal of Clinical & Experimental Cardiology Suppl 10(6): 1-9, 2013

Depot antipsychotics may reduce risk of relapse compared with oral antipsychotics in people with schizophrenia. 2011

Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatric Services 58(4): 482-488, 2007

Review: depot antipsychotics may reduce risk of relapse compared with oral antipsychotics in people with schizophrenia. Evidence-Based Mental Health 14(4): 112-112, 2011

Intervals between hospitalisations in schizophrenia patients under antipsychotics in depot-form versus oral second generation antipsychotics. Psychiatrische Praxis 34(6): 289-291, 2007

Depot Typical Antipsychotics versus Oral Atypical Antipsychotics in Relapse Rate Among Patients with Schizophrenia: A Five -Year Historical Cohort Study. Iranian Journal of Psychiatry and Behavioral Sciences 8(1): 66-71, 2014

Review: depot antipsychotics are effective and safe for schizophrenia or schizophrenia like illnesses. Evidence-Based Mental Health 5(2): 42-42, 2002

Adjusting for geographic variation in observational comparative effectiveness studies: a case study of antipsychotics using state Medicaid data. Bmc Health Services Research 14(): 355-355, 2015

Trends in use of antipsychotics and mood stabilizers among Medicaid beneficiaries with bipolar disorder, 2001-2004. Psychiatric Services 59(10): 1169-1174, 2008

The effect of medicaid expansion in new york state on use of subspecialty surgical procedures by medicaid beneficiaries and the uninsured. Journal of the American College of Surgeons 218(5): 889-897, 2014

Access to Care for Medicare-Medicaid Dually Eligible Beneficiaries: The Role of State Medicaid Payment Policies. Health Services Research (): -, 2016

Switching from depot antipsychotics to risperidone: results of a study of chronic schizophrenia. The Schizophrenia Treatment & Assessment Group. Advances in Therapy 16(2): 78-88, 1999

Effects of state-level medicaid policies and patient characteristics on time to breast cancer surgery among medicaid beneficiaries. Breast Cancer Research and Treatment 158(3): 573-581, 2016

Perceptions on efficacy and side effects of conventional depot antipsychotics (CDA) and atypical depot antipsychotics (ADA): Psychiatrists versus patients in Hong Kong. International Journal of Psychiatry in Clinical Practice 14(1): 23-32, 2010